1386 related articles for article (PubMed ID: 22414958)
1. Retreatment with anti-vascular endothelial growth factor therapy based on changes in visual acuity after initial stabilization of neovascular age-related macular degeneration: 3-year follow-up results.
Dunavoelgyi R; Sacu S; Eibenberger K; Palkovits S; Leydolt C; Pruente C; Schmidt-Erfurth U
Retina; 2012 Sep; 32(8):1471-9. PubMed ID: 22414958
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of 12-month treatment of neovascular age-related macular degeneration with intravitreal bevacizumab based on individually determined injection strategies after three consecutive monthly injections.
Mekjavic PJ; Kraut A; Urbancic M; Lenassi E; Hawlina M
Acta Ophthalmol; 2011 Nov; 89(7):647-53. PubMed ID: 19860774
[TBL] [Abstract][Full Text] [Related]
3. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
[TBL] [Abstract][Full Text] [Related]
4. Bevacizumab for neovascular age-related macular degeneration in China.
Li X; Hu Y; Sun X; Zhang J; Zhang M;
Ophthalmology; 2012 Oct; 119(10):2087-93. PubMed ID: 22818896
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab for neovascular age-related macular degeneration using a treat-and-extend regimen: clinical and economic impact.
Shienbaum G; Gupta OP; Fecarotta C; Patel AH; Kaiser RS; Regillo CD
Am J Ophthalmol; 2012 Mar; 153(3):468-473.e1. PubMed ID: 21996309
[TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab versus combined intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration: six-month results of a randomized clinical trial.
Ahmadieh H; Taei R; Riazi-Esfahani M; Piri N; Homayouni M; Daftarian N; Yaseri M
Retina; 2011 Oct; 31(9):1819-26. PubMed ID: 21555967
[TBL] [Abstract][Full Text] [Related]
7. Fixed-interval versus OCT-guided variable dosing of intravitreal bevacizumab in the management of neovascular age-related macular degeneration: a 12-month randomized prospective study.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Am J Ophthalmol; 2012 Mar; 153(3):481-489.e1. PubMed ID: 22014603
[TBL] [Abstract][Full Text] [Related]
8. Long-term outcome of subretinal coapplication of rtPA and bevacizumab followed by repeated intravitreal anti-VEGF injections for neovascular AMD with submacular haemorrhage.
Treumer F; Roider J; Hillenkamp J
Br J Ophthalmol; 2012 May; 96(5):708-13. PubMed ID: 22174095
[TBL] [Abstract][Full Text] [Related]
9. Systemic beta-blockers may reduce the need for repeated intravitreal injections in patients with wet age-related macular degeneration treated by bevacizumab.
Montero JA; Ruiz-Moreno JM; Sanchis-Merino E; Perez-Martin S
Retina; 2013 Mar; 33(3):508-12. PubMed ID: 23099497
[TBL] [Abstract][Full Text] [Related]
10. Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration.
Simader C; Ritter M; Bolz M; Deák GG; Mayr-Sponer U; Golbaz I; Kundi M; Schmidt-Erfurth UM
Ophthalmology; 2014 Jun; 121(6):1237-45. PubMed ID: 24684838
[TBL] [Abstract][Full Text] [Related]
11. Intravitreal bevacizumab in the management of neovascular age-related macular degeneration: effect of baseline visual acuity.
El-Mollayess GM; Mahfoud Z; Schakal AR; Salti HI; Jaafar D; Bashshur ZF
Retina; 2013 Oct; 33(9):1828-35. PubMed ID: 23615342
[TBL] [Abstract][Full Text] [Related]
12. Super-dose anti-VEGF (SAVE) trial: 2.0 mg intravitreal ranibizumab for recalcitrant neovascular macular degeneration-primary end point.
Brown DM; Chen E; Mariani A; Major JC;
Ophthalmology; 2013 Feb; 120(2):349-54. PubMed ID: 23131717
[TBL] [Abstract][Full Text] [Related]
13. Prospective study of intravitreal triamcinolone acetonide versus bevacizumab for macular edema secondary to central retinal vein occlusion.
Ding X; Li J; Hu X; Yu S; Pan J; Tang S
Retina; 2011 May; 31(5):838-45. PubMed ID: 21293319
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy of three intravitreal injections of bevacizumab in the treatment of exudative age-related macular degeneration].
Bidot ML; Malvitte L; Bidot S; Bron A; Creuzot-Garcher C
J Fr Ophtalmol; 2011 Jun; 34(6):376-81. PubMed ID: 21550687
[TBL] [Abstract][Full Text] [Related]
15. Intravitreal bevacizumab treatment for exudative age-related macular degeneration with good visual acuity.
Axer-Siegel R; Bor E; Bourla DH; Weinberger D; Mimouni K
Retina; 2012 Oct; 32(9):1811-20. PubMed ID: 22825407
[TBL] [Abstract][Full Text] [Related]
16. Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial.
Kodjikian L; Souied EH; Mimoun G; Mauget-Faÿsse M; Behar-Cohen F; Decullier E; Huot L; Aulagner G;
Ophthalmology; 2013 Nov; 120(11):2300-9. PubMed ID: 23916488
[TBL] [Abstract][Full Text] [Related]
17. Effect of intravitreal bevacizumab (Avastin) in neovascular age-related macular degeneration using a treatment regimen based on optical coherence tomography: 6- and 12-month results.
Leydolt C; Michels S; Prager F; Garhoefer G; Georgopoulos M; Polak K; Schmidt-Erfurth U
Acta Ophthalmol; 2010 Aug; 88(5):594-600. PubMed ID: 19485959
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab injection for neovascular age-related macular degeneration in phakic versus pseudophakic eyes.
Baek JS; Cho HJ; Cho SW; Kim CG; Kim JW
Retina; 2013 Mar; 33(3):467-73. PubMed ID: 23400082
[TBL] [Abstract][Full Text] [Related]
19. Time to first treatment: The significance of early treatment of exudative age-related macular degeneration.
Rauch R; Weingessel B; Maca SM; Vecsei-Marlovits PV
Retina; 2012 Jul; 32(7):1260-4. PubMed ID: 22186738
[TBL] [Abstract][Full Text] [Related]
20. Treat-and-extend bevacizumab for neovascular age-related macular degeneration: the importance of baseline characteristics.
Rush RB; Simunovic MP; Vandiver L; Aragon AV; Ysasaga JE
Retina; 2014 May; 34(5):846-52. PubMed ID: 24240560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
